Biopharmx Corp (BPMX) Short Interest Update
Biopharmx Corp (NYSEAMERICAN:BPMX) was the target of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 5,070,482 shares, a decline of 0.7% from the November 15th total of 5,108,040 shares. Based on an average daily volume of 4,382,333 shares, the short-interest ratio is presently 1.2 days. Approximately 4.9% of the company’s shares are sold short.
In other Biopharmx news, major shareholder Vivo Capital Viii, Llc sold 296,394 shares of Biopharmx stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $0.20, for a total transaction of $59,278.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Stephen Morlock bought 330,000 shares of Biopharmx stock in a transaction on Friday, November 24th. The shares were acquired at an average price of $0.15 per share, for a total transaction of $49,500.00. The disclosure for this purchase can be found here.
Shares of Biopharmx (NYSEAMERICAN BPMX) opened at $0.11 on Wednesday. Biopharmx has a 12-month low of $0.11 and a 12-month high of $0.90.
Several research analysts have weighed in on BPMX shares. Maxim Group reiterated a “buy” rating and set a $1.50 target price on shares of Biopharmx in a report on Friday, December 8th. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of Biopharmx in a report on Tuesday, September 19th.
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.